Shilpa Medicare has completed US Food and Drug Administration (USFDA) audit at its API site, Raichur between July 22, 2019 and July 26, 2019. The company has received Form 483 with 5 observations, with no repeat observations and any data integrity observations. The observations are mostly procedural in nature.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1677.45 |
| Dr. Reddys Lab | 1234.80 |
| Cipla | 1241.25 |
| Zydus Lifesciences | 948.10 |
| Lupin | 2332.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: